Molecular and survival differences between familial and sporadic gastric cancers

Wen Liang Fang, Shih Ching Chang, Yuan Tzu Lan, Kuo Hung Huang, Su Shun Lo, Anna Fen Yau Li, Chin Wen Chi, Chew Wun Wu, Shih Hwa Chiou*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Mismatch repair (MMR) and germline E-cadherin (CDH1) mutations are two of the major pathways of carcinogenesis in familial gastric cancer (GC). A total of 260 sporadic and 66 familial GC patients were enrolled and molecular and survival differences were compared. Familial GC patients had earlier onset and were diagnosed at an earlier stage and had both a better 5-year overall survival rate and 3-year disease-free survival rate compared with sporadic GC patients. Only in diffuse type GC, the MSI-H phenotype and abnormal MMR protein expression were significantly higher in familial GC than in sporadic GC. In MSI-H GC, MLH1 promoter methylation was slightly higher in sporadic GC than familial GC (50% versus 23.1%), while the frequency of MMR gene mutation was slightly higher in familial GC than in sporadic GC (15.4% versus 3.1%). All of the patients with MMR gene mutation had diffuse type GC. Among familial GC patients with CDH1 mutation, most patients (72.3%) had diffuse type GC. In summary, for familial GC patients, we recommend screening of MSI status and CDH1 mutation especially for diffuse type GC. Because of the low incidence, mutation analysis of MMR gene might be considered in MSI-H familial GC with diffuse type only.

Original languageEnglish
Article number396272
JournalBioMed Research International
Volume2013
DOIs
StatePublished - 2013

Fingerprint

Dive into the research topics of 'Molecular and survival differences between familial and sporadic gastric cancers'. Together they form a unique fingerprint.

Cite this